Kyowa Kirin (4151) Q4 2024 earnings summary

Executive summary

• FY2024 revenue rose 12% to ¥495.6B, driven by global product growth and tech out-licensing, with overseas sales ratio increasing to 72%.

• Strategic focus on unmet medical needs, global expansion, R&D, and new partnerships, including major acquisitions and product launches.

• Major investments in R&D, acquisitions (Orchard Therapeutics), and manufacturing capacity to support long-term growth.

• R&D pipeline advanced with key milestones for rocatinlimab and ziftomenib.

• Environmental initiatives led to a 67% reduction in GHG emissions (Scope 1, 2) compared to 2019.

Financial highlights

• Gross profit increased to ¥362.9B (up 10%), but gross margin declined to 73% due to higher COGS.

• Core operating profit fell 1% to ¥95.4B; profit dropped 26% to ¥59.9B, mainly from one-time items and higher R&D.

• R&D expenses surged 44% to ¥103.5B, raising the R&D ratio to 21%.

• Operating cash flow dropped 41% to ¥67.9B; investing cash outflow rose to ¥142.4B, mainly for acquisitions and intangibles.

• Dividend payout ratio increased to 47.8%; share buyback of ¥40B executed, total return ratio at 109.6%.

Outlook and guidance

• FY2025 revenue expected to decline 4% to ¥478.0B, mainly due to APAC restructuring, EMEA one-time items, and FX impact.

• Core operating profit forecast to drop 16% to ¥80.0B; profit to decrease 5% to ¥57.0B.

• R&D investment to remain high at ¥107.0B (22% of revenue), focusing on late-stage pipeline and new launches.

• Dividend per share projected to increase to ¥60, marking nine consecutive years of increases.

• ROE target of 10% delayed to 2026 or later due to increased R&D and business model changes.